The Game-Changing Trend Reshaping Cancer Profiling Market Size and Growth in 2025

 The Business Research Company’s report on the Cancer Profiling Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.

 
 Which emerging drivers are set to accelerate the growth of the cancer profiling market further?
 The increasing incidence of cancer is expected to propel the growth of the cancer profiling market going forward. Incidence of cancer refers to the number of new cancer cases in a specific population for a given period. The increased incidence of cancer caused due to urbanization, a growing aging population, changing lifestyles, and environmental and genetic factors. Cancer profiling aids in the identification of specific molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA, which is helpful in the cancer treatment cycle. For instance, in 2022, according to the American Cancer Society, a US-based voluntary organization, the number of new cancer cases and fatalities expected was estimated to be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States. Therefore, the increasing incidence of cancer is driving the growth of the cancer profiling market.
 
 Access Your Free Sample of the Global Cancer Profiling Market Report — Get Insights Now!
 https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp
 
 What are the key factors influencing the forecasted market size of the cancer profiling industry?
 The cancer profiling market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15.05 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing cancer incidence rates, rise in precision medicine approaches, clinical adoption of biomarkers, drug development and targeted therapies, awareness, and patient advocacy.
 
 The cancer profiling market size is expected to see rapid growth in the next few years. It will grow to $23.08 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to integration of artificial intelligence, global collaborations in research, expansion of liquid biopsy applications, regulatory support for precision medicine, increasing emphasis on early detection. Major trends in the forecast period include liquid biopsy dominance, comprehensive genomic profiling, rise of immunoprofiling, collaborative data sharing network, single-cell sequencing.
 
 Gain Exclusive Market Insights — Customize Your Research Report Today For Fast Delivery!
 https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp
 
 Who are the leading competitors in the cancer profiling market?
 Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation
 
 Which emerging trends are set to transform the cancer profiling market landscape?
 Major companies operating in the cancer profiling market are focused on developing innovation, such as broad coverage. The test evaluates 517 cancer-relevant genes across nearly 30 solid tumor types. Broad coverage refers to the comprehensive analysis of a wide range of genetic mutations, biomarkers, or molecular targets. For instance, in March 2022, Illumina, Inc., a US-based biotechnology company, launched the TruSight Oncology Comprehensive (TSO) test, marking a significant advancement in cancer diagnostics. A new in vitro diagnostic test in Europe profiles cancer mutations to guide patients toward targeted therapies. It covers 517 genes across nearly 30 solid tumor types, analyzing both DNA and RNA. With a four- to five-day turnaround, it delivers faster results and is CE-marked for European quality standards, reducing the need for multiple gene assays on different tissue samples.
 
 How do different geographies compare in terms of market share and growth potential in the cancer profiling market?
 North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Order Your Report Now For Swift Delivery
 https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report
 
 Which major segments of the cancer profiling market are experiencing the fastest growth?
 The cancer profiling market covered in this report is segmented –
 
 1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization
 2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers
 3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers
 4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications
 
 Subsegments:
 1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays
 2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)
 3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)
 4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays
 5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)
 
 Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
 https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912
 
 How is the cancer profiling market defined, and what are its core characteristics?
 Cancer profiling refers to a diagnostic procedure that is conducted to analyze the genetic information of tumor cells in the body. It provides information about certain molecular or genetic changes in a tumor, such as gene mutations or other changes in tumor DNA.
 
 About The Business Research Company:
 
 With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead. 
 
 Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making. 
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/
 
 Europe: +44 207 1930 708 
 
 Asia: +91 88972 63534 
 
 Americas: +1 315 623 0293 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company